Radezolid

N/A

Report date: 2022/07/19 20:00:45
NMEQIDP

Base Information

Drug NameRadezolid
Drug Alias Name雷德唑胺Radezolidum雷迪唑烷雷得唑来RX-103 +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action50S ribosomal subunit inhibitors
Targets50S ribosomal subunit
Therapy Area/IndicationsAbscessSkin Diseases, InfectiousPneumonia +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesRussian Federation
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMelinta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMelinta Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsAbscessSkin Diseases, InfectiousPneumonia +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG